Vault complexes for facilitating biomolecule delivery
US-9181312-B2 · Nov 10, 2015 · US
Vault complexes for cytokine delivery
US9597372B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9597372-B2 |
| Application number | US-201414553146-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 25, 2014 |
| Priority date | Nov 2, 2009 |
| Publication date | Mar 21, 2017 |
| Grant date | Mar 21, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to compositions of vault complexes containing recombinant cytokine fusion proteins that include a cytokine and a vault targeting domain, and methods of using the vault complexes to deliver the cytokines to a cell or subject, and methods for using the compositions to treat cancer, such as lung cancer.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of preparing a composition comprising a vault complex, said vault complex comprising a vault particle and a cytokine fusion protein, the method comprising a) mixing the cytokine fusion protein with the vault particle to generate a mixture, wherein the cytokine fusion protein comprises a cytokine and a vault targeting domain, which said vault targeting domain is a vault poly ADP-ribose polymerase (VPARP) sequence or a portion thereof that interacts with the major vault protein, or a telomerase/vault associated protein 1 (TEP 1) sequence or a portion thereof that interacts with the major vault protein, and wherein the vault particle comprises a major vault protein (MVP); and b) incubating the mixture for a sufficient period of time to allow non-covalent association of the cytokine fusion protein with the vault particle, thereby generating the vault complex. 2. The method of claim 1 , wherein the MVP is human MVP. 3. The method of claim 1 , wherein the cytokine fusion protein and the MVP are generated in Sf9 or insect larvae cells. 4. The method of claim 1 , wherein the vault targeting domain is a) a vault poly-ADP ribose polymerase (VPARP) sequence or a portion thereof that interacts with the MVP; or b) a telomerase/vault associated protein 1 (TEP 1) sequence or a portion thereof that interacts with the MVP. 5. The method of claim 1 , wherein the cytokine fusion protein is non-covalently associated with the vault particle. 6. The method of claim 1 , wherein the cytokine is a chemokine. 7. The method of claim 6 , wherein the chemokine is a cysteine-cysteine (CC) chemokine. 8. The method of claim 7 , wherein the CC chemokine is a CCL-21 chemokine. 9. The method of claim 1 , wherein the cytokine comprises the amino acid sequence of SEQ ID NO: 2. 10. The method of claim 4 , wherein the vault targeting domain is the portion of the VPARP that is a major vault protein interaction (mINT) domain. 11. The method of claim 10 , wherein the mINT domain comprises the amino acid sequence of SEQ ID NO: 8. 12. The method of claim 1 , wherein the cytokine fusion protein comprises the amino acid sequence of SEQ ID NO: 13.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9597372B2 cover?
- The invention relates to compositions of vault complexes containing recombinant cytokine fusion proteins that include a cytokine and a vault targeting domain, and methods of using the vault complexes to deliver the cytokines to a cell or subject, and methods for using the compositions to treat cancer, such as lung cancer.
- Who is the assignee on this patent?
- Univ California, Us Veterans Affairs
- What technology area does this patent fall under?
- Primary CPC classification A61K38/195. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).